TRIB — TRINITY BIOTECH PLC
As of Q2 2026, 4 SEC-registered investment managers reported holding TRIB (TRINITY BIOTECH PLC) in their latest 13F filings, with a combined reported value of $6.46K across 16.61K shares. That is -68.4% by share count (-35.91K shares) versus the previous quarter, while reported value moved -77.3%. Ownership is concentrated: the five largest holders account for 100.0% of reported value and the top ten for 100.0%.
Compared with the prior quarter, 1 added to existing stakes, 1 trimmed, 2 exited entirely. 13F holdings are quarter-end snapshots, so these moves reflect positioning as of Q2 2026, not real-time trading.
TRIB is classified in the Health Care sector.
All figures on this page are computed from SEC Form 13F quarterly filings. 13F filers disclose long positions of $100,000 or more within 45 days of quarter end; short positions, options overlays and intra-quarter trades are not included, so treat the numbers as a quarterly snapshot of institutional ownership rather than real-time positioning.
| Fund | Quarter | Shares | Value | Portfolio Weight | Change |
|---|---|---|---|---|---|
| Two Sigma Investments history | Q4 2025 | 18.65K | $14.75K | 0.00% | Reduce |
| Renaissance Technologies history | Q1 2026 | 17.76K | $9.63K | 0.00% | Reduce |
| Citadel Advisors history | Q1 2026 | 14.20K | $7.70K | 0.00% | Reduce |
| Geode Capital Management history | Q2 2026 | 12.60K | $4.90K | 0.00% | Reduce |
| Wells Fargo & Co history | Q2 2026 | 2.50K | $972 | 0.00% | Hold |
| Bank of America Corp history | Q4 2025 | 1.09K | $867 | 0.00% | Add |
| UBS Group AG history | Q2 2026 | 1.11K | $431 | 0.00% | Add |
| Morgan Stanley history | Q2 2026 | 400 | $156 | 0.00% | Hold |
| Fidelity Management & Research (FMR) history | Q4 2025 | 11 | $9 | 0.00% | New |
New Positions (Q2 2026)
No fund opened a new position this quarter.
Fully Exited (vs previous quarter)
- Renaissance Technologies sold 17.76K sh · $9.63K
- Citadel Advisors sold 14.20K sh · $7.70K
Fund Position History — shares by quarter (top 9 funds)
| Fund | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Geode Capital Management | — | — | — | 17.68K | 16.64K | 16.64K | 16.64K | 16.64K | 16.64K | 12.60K |
| Wells Fargo & Co | — | — | — | — | — | — | — | — | 2.50K | 2.50K |
| UBS Group AG | 5.18K | — | — | 10.62K | — | — | 51 | 780 | 1.01K | 1.11K |
| Morgan Stanley | 2.91K | 2.66K | 2.66K | 2.16K | 2.16K | — | 480 | 580 | 402 | 400 |
| Citadel Advisors | — | 16.33K | 14.15K | — | 68.24K | 13.30K | 39.38K | 37.50K | 14.20K | — |
| Fidelity Management & Research (FMR) | — | — | — | — | — | — | — | 11 | — | — |
| Renaissance Technologies | 267.35K | 265.45K | 250.15K | 189.05K | 76.67K | 56.97K | 171.36K | 20.26K | 17.76K | — |
| Two Sigma Investments | — | — | — | — | 15.07K | 15.07K | 23.99K | 18.65K | — | — |
| Bank of America Corp | 240 | 240 | 240 | 240 | 40 | 80 | 40 | 1.09K | — | — |
▲ Bought Low (fund opened/added, stock rose ≥5% next quarter) ▼ Sold High (fund reduced, stock fell ≥5% next quarter)
Drag / scroll to zoom · Default shows the most recent year · Annotations come from quarterly fund actions in 13F filings · Hover a marker for details